MEN1 and neuroendocrine carcinoma: No significant differences were observed in the prevalence of MEN1, DAXX, or ATRX mutations, tumor mutation burden, microsatellite status, or PD-L1 status between NEC-like G3NETs and non-NEC-like G3NETs.